[ET Net News Agency, 9 May 2018] China Medical System (CMS) (00867) said Faron
Pharmaceuticals Ltd announced top line data from its pan-European Phase III INTEREST
trial.
The INTEREST study did not meet the Day 28 (D28) primary efficacy composite endpoint of
ventilator free days and survival with Traumakine treatment.
The INTEREST trial was a Phase III double-blind, randomised, parallel-group comparison
to assess the efficacy and safety of Traumakine (FP-1201-lyo) versus placebo in the
treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS).
CMS believes that, under the current circumstances, the product will not be able to
obtain the necessary regulatory approval for it to be marketed based on the above results.
While the results of the clinical trial are disappointing, the directors of CMS do not
believe that they have any material impact on the financial results of the Group.
Trading in shares of CMS will be resumed today. (HL)